Physician profile
Lauren E Barry
NPI 1669784815
$4,848.05
in general payments reported to CMS, 2019-2025
35 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $443 · 2021: $1,019 · 2022: $717 · 2023: $481 · 2024: $226 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,326.10 | 2019-2020 | |
| Abbvie INC. | $861.74 | 2019-2023 | Lo Loestrin Fe, Liletta, Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $325.66 | 2019-2025 | Trintellix |
| Pfizer INC. | $241.58 | 2019-2023 | |
| Amgen INC. | $202.69 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $202.36 | 2021-2025 | |
| Astellas Pharma US INC | $123.54 | 2019-2025 | Veozah |
| Urovant Sciences INC | $118.81 | 2022 | |
| Therapeuticsmd, INC. | $111.45 | 2019-2021 | |
| Hologic Sales and Service, LLC | $110.32 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Coopersurgical, INC. | $107.48 | 2019-2021 | |
| Genzyme Corporation | $92.07 | 2021 | |
| Organon LLC | $91.55 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $87.41 | 2020-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.69 | 2020-2023 | Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $85.48 | 2019 | |
| Myovant Sciences INC. | $80.51 | 2021-2022 | |
| Exeltis, USA INC. | $79.45 | 2021-2023 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $79.02 | 2023-2025 | |
| Shield Therapeutics INC | $60.81 | 2022-2023 | Accrufer |
| Alexion Pharmaceuticals, INC. | $48.02 | 2022-2023 | Ultomiris |
| Becton, Dickinson and Company | $37.80 | 2023 | Bd Onclarity |
| Avion Pharmaceuticals | $35.10 | 2020-2023 | Balcoltra |
| Axsome Therapeutics, INC. | $29.25 | 2022-2023 | Auvelity |
| Novo Nordisk INC | $28.34 | 2021 | |
| Radius Health, INC. | $27.75 | 2020 | |
| Evofem Biosciences, INC. | $27.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.23 | 2019-2021 | |
| Lupin INC. | $24.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.55 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.65 | 2024 | |
| Eisai INC. | $17.25 | 2021 | |
| Scynexis, INC. | $14.00 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $11.76 | 2022 | |
| Boston Scientific Corporation | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.